Lupin gets final USFDA nod for Mylan's skin disease cream
New Delhi : Pharma major Lupin said it has received final approval from the US health regulator to market its generic version of Mylan's triamcinolone acetonide cream used for treatment of skin disease.
The approval is for multiple strengths of
0.025 per cent, 0.1 per cent and 0.5 per cent triamcinolone acetonide cream which is used for relief from inflammatory and pruritic manifestations of corticosteroid responsive dermatoses, the company said in a BSE filing.
"Lupin shall commence promoting the product shortly," it added.
Citing IMS MAT data up to September 2016, Lupin said triamcinolone acetonide cream had sales of USD 55.7 million in the US market.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd